Everything will change…
Göttingen, 20.02.2024: A lot will change for us soon. More information coming soon.
We welcome Jörn Tolstrup as Senior Clinical Trial Manager in our team
Goettingen, Germany, March 4, 2022 - With Jörn Tolstrup, PhD we strengthen our team. He joins Curexsys to be responsible for all clinical operations [...]
We´ve moved
As the first company, alongside the Life Science Factory team, we moved to the new Sartorius quarter on Weender Landstrasse on January 1st, 2022. [...]
Curexsys Appoints Christian Eckert as Chief Operating Officer
- Strengthened management team headed by Jörg Neermann as CEO Goettingen, Germany, October 20, 2021 - Curexsys GmbH, a leader in the emerging field [...]
Curexsys acquires new IP
Curexsys acquires a family of patents (EP2195430 & EP 3199633, US8729038 & US9951329, CA2699638, JP2010538625) enabling both targeted delivery of therapeutics and transfer of [...]
Curexsys Researchers Co-Present two Studies at the annual ESGCT Meeting
Curexsys researchers contribute to two studies that will be presented at the annual meeting of the European Society for Cell and Gene Therapy (ESGCT [...]
Jörg Neermann joins Curexsys as CEO
Göttingen, Germany, May 1, 2021 – Curexsys GmbH, a new, pre-clinical stage therapeutic company developing iMSC derived exosomes for age-related diseases and anti-aging therapies, [...]
Michael Shalmi joins Curexsys’ board of directors as Chairman of the Supervisory Board
Göttingen, Germany, April 1, 2021 – Curexsys GmbH, a new, pre-clinical stage therapeutic company developing iMSC derived exosomes for age-related diseases and anti-aging therapies, [...]
Press Release: Evotec und Sartorius finance Curexsys
Evotec and Sartorius partner with Start-Up Curexsys on iPSC-based therapeutic exosome approach. Download Press Release